ACE2 is the SARS COV-2 receptor required for cell entry

NEJM Jwatch with references: Although offering a promising therapeutic and vaccine target against SARS-CoV-2, these new findings remind us that the viral pathogenesis of COVID-19 focuses on blood-pressure homeostasis mediated by the renin-angiotensin system (Future Virology 2010; 5:145). High risk for severe COVID-19 disease has been assumed to be driven largely by waning innate immunity that comes with advanced age, but younger patients with cardiovascular disease or hypertension may have unappreciated risk

Link

Leave a Reply

Your email address will not be published. Required fields are marked *